Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney CancerBusiness Wire • 06/03/26
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 05/26/26
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/05/26
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline UpdateBusiness Wire • 05/05/26
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 04/28/26
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?Zacks Investment Research • 04/22/26
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline UpdatesBusiness Wire • 04/21/26
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline UpdateBusiness Wire • 02/25/26
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney CancerBusiness Wire • 02/23/26
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline UpdatesBusiness Wire • 02/11/26
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High?Zacks Investment Research • 02/04/26
Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation ProgramsBusiness Wire • 01/07/26
Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual ReturnThe Motley Fool • 01/06/26
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/18/25